Femasys reported a first-half 2026 net loss of $3.62 million, improving by nearly $6.9 million from a $10.48 million loss a year earlier, even though its underlying operating loss was essentially unchanged at approximately $9.29 million versus $9.31 million. The biotechnology company subsequently completed a $30 million private placement, with associated warrants carrying the potential to generate up to another $90 million upon full cash exercise.
The substantial improvement in reported net loss therefore did not come primarily from stronger operating profitability. Femasys recorded a first-half loss from operations of $9.289 million compared with $9.312 million in the prior-year period, a difference of less than $23,000.
Instead, much of the improvement occurred below the operating line. Femasys recorded approximately $1.73 million of favorable changes in the fair value of its conversion option liability and $4.23 million from changes in the fair value of warrant liabilities during the first half. Neither category contributed comparable income in the first half of 2025.
Those fair-value changes helped swing total other income and expense to positive $5.67 million in the first half of 2026 from negative $1.17 million a year earlier. That accounting swing explains most of the difference between the nearly unchanged operating loss and the much narrower reported net loss.
Interest expense also decreased to approximately $363,000 from $951,000, providing another benefit below the operating line. First-half net loss per basic and diluted share attributable to common stockholders improved to $1.08 from $7.76.
At the operating level, first-half sales increased just 0.8% to $756,716 from $750,532, with Femasys attributing the increase primarily to FemaSeed. Research and development expense decreased 25.7% to $3.26 million from $4.38 million, primarily reflecting lower compensation, regulatory and professional service costs.
The reduction in R&D was largely offset elsewhere in the expense structure. Sales and marketing expense increased to $2.61 million from $1.89 million, while general and administrative expense increased to $3.71 million from $3.34 million. Total operating expenses were therefore nearly unchanged at approximately $9.75 million compared with $9.79 million.
Second-quarter results showed a different operating pattern than the six-month figures. Q2 sales declined 18.9% to $331,827 from $409,268, primarily because of lower FemVue sales, while R&D expense increased 37.6% to $1.95 million as clinical costs increased. Quarterly net loss narrowed modestly to $4.47 million from $4.59 million.
Femasys’ liquidity position at the end of Q2 made the subsequent financing particularly significant. The company had only $1.44 million of cash and equivalents at June 30, down from $9.27 million at the end of 2025, along with an accumulated deficit of approximately $149.4 million.
After quarter-end, Femasys completed the private placement and generated approximately $30 million of gross proceeds. The company said the additional capital is intended to support execution of its commercial initiatives, advancement of clinical programs and other key operating objectives.
The financing also includes warrants that could produce up to $90 million of potential proceeds upon full cash exercise. Those proceeds are not guaranteed because they depend on the warrants ultimately being exercised for cash, but they create a potentially much larger future capital source beyond the $30 million already raised.
Femasys intends to deploy capital across both commercialization and clinical development. The company has launched FemaSeed Complete and advanced its initial commercial use in OB/GYN offices, positioning the fertility treatment as a potential earlier intervention in the patient care pathway. It also launched FemaSeed Complete at ACOG 2026 to increase awareness among providers.
The other major capital priority is FemBloc, Femasys’ nonsurgical, in-office permanent birth-control candidate. The company is advancing FemBloc toward potential U.S. FDA approval through the ongoing FINALE pivotal trial. FemBloc previously received regulatory approvals in Europe, the U.K. and New Zealand in 2025.
The combination of the financing and first-half results creates two distinct financial stories. Femasys’ reported net loss improved dramatically, but operating losses remained essentially unchanged and the improvement was driven largely by fair-value accounting changes below the operating line. Separately, the $30 million private placement materially strengthened a balance sheet that held only $1.4 million of cash at quarter-end, while warrant exercises could potentially provide substantially more capital to support commercialization and FemBloc development.
KEY QUOTES:
“During the second quarter of 2026 and into the third quarter of 2026, we made meaningful progress strengthening our financial position, advancing our commercial strategy and expanding the reach of our innovative fertility solutions. The completion of our $30 million private placement and restoration of Nasdaq compliance provide a stronger foundation to execute our growth strategy. We also achieved important commercial milestones, including the launch of FemaSeed Complete at ACOG 2026 and initial commercial use, advancing our strategy to expand access to first-line fertility treatment in the OB/GYN office and potentially enable earlier intervention. With this financing in place, we are well positioned to execute our commercial strategy, complete the U.S. FemBloc clinical program and advance our portfolio toward key value-creating milestones for patients and shareholders.”
Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys
